Oncolytic Vaccinia Viruses and Recombinant Viruses and Methods of Use Thereof
Summary
The USPTO published patent application US20260097116A1 by ViroMissile, Inc. covering clonal strains of vaccinia virus engineered as oncolytic virus therapies for treating cancer. The application includes claims for recombinant vaccinia viruses with inactivating mutations and heterologous gene products, pharmaceutical compositions, and methods of use for anti-tumor therapy.
What changed
The USPTO published a patent application for oncolytic vaccinia virus compositions and methods of use. The application covers clonal vaccinia virus strains engineered with inactivating mutations in viral genes and heterologous nucleic acids encoding gene products for enhanced anti-tumor activity.
This patent publication establishes prior art for entities developing competing oncolytic virus therapies or similar vaccinia-based cancer treatments. Researchers and biotech companies in the virotherapy space should review the claims for potential freedom-to-operate concerns or licensing opportunities.
What to do next
- Monitor for updates
Archived snapshot
Apr 13, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF
Application US20260097116A1 Kind: A1 Apr 09, 2026
Assignee
ViroMissile, Inc.
Inventors
Nanhai George CHEN
Abstract
Provided herein are clonal strains of a vaccinia virus that exhibits enhanced anti-tumor properties and/or reduced immunogenicity, and recombinant vaccinia virus derived from the same. Also provided herein are recombinant oncolytic virus strains that include an inactivating mutation in one or more viral genes, and/or one of more heterologous nucleic acids each encoding one or more heterologous gene products. The viruses, e.g., vaccinia viruses, provided herein, including recombinant vaccinia viruses, can be used as an oncolytic virus therapy, e.g., an oncolytic vaccinia virus therapy, for treating cancer. Also provided herein are pharmaceutical compositions and methods and uses of the viruses, e.g., vaccinia viruses, for treating cancer, as well as nucleic acids encoding the viruses.
CPC Classifications
A61K 39/285 A61K 9/0019 A61K 31/451 A61K 45/06 A61P 35/00 A61K 2039/5252 A61K 2039/54
Filing Date
2025-12-10
Application No.
19414525
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.